Profile
Peter W.
Letendre served as President, Chief Executive Officer & Director at Pier Pharmaceuticals, Inc. and as a Director at RespireRx Pharmaceuticals, Inc. He was also the Chief Commercial Officer at Replidyne, Inc. from 2005 to 2008.
Letendre received his undergraduate degree in 1980 and his doctorate in 1982 from Massachusetts College of Pharmacy & Health Science.
Former positions of Peter W. Letendre
| Companies | Position | End |
|---|---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Develops and commercializes novel antibiotics to treat infections caused by drug resistant bacteria | Corporate Officer/Principal | 15/04/2008 |
| RESPIRERX PHARMACEUTICALS INC. | Director/Board Member | - |
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for sleep apnea | Chief Executive Officer | - |
Training of Peter W. Letendre
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
RespireRx Pharmaceuticals, Inc.
RespireRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates biopharmaceutical company that discovers and develops drug therapies for the treatment of sleep apnea, respiratory depression & other brain-mediated breathing disorders | Health Technology |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Develops and commercializes novel antibiotics to treat infections caused by drug resistant bacteria | Health Technology |
Massachusetts College of Pharmacy & Health Science
Massachusetts College of Pharmacy & Health Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for sleep apnea | Health Technology |
- Stock Market
- Insiders
- Peter W. Letendre
















